InterVapor for Emphysema or COPD
Post-Market BTVA Registry
Recruiting
Observational Study
Emphysema or COPD
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Uptake Medical Technology, Inc. · Industry
Who this trial is looking for
This trial is looking for patients with a specific type of emphysema to participate in a registry. Participants will receive treatment and be followed for 5 years to see how it affects their quality of life and lung function.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with heterogeneous emphysema
- I am at least 18 years old
- I can provide informed consent
You may not be able to join if
- My lung function (FEV1) is below 20% of what is expected
- My lung diffusion capacity (DLCO) is below 20% of what is expected
- I cannot walk more than 140 meters in 6 minutes
- I have been hospitalized for COPD and needed antibiotics more than 3 times in the past 12 months
- I have been hospitalized for COPD in the past 3 months
- I use systemic steroids daily
- I have a significant health condition that increases my risk of complications
- I am currently pregnant or breastfeeding
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is a retrospective and prospective, observational, multi-center, post-market registry of patients prescribed InterVapor. The primary objective of the Registry is to describe the long-term impact of InterVapor treatm…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients will have heterogeneous emphysema, as evidenced by high-resolution computed tomography (HRCT) demonstrating a heterogeneity index \> or equal to 1.2 in at least one segment to be treated
2. Patients must be \> or equal to 18 years of age
3. Patients are required to p…
Contacts